147 related articles for article (PubMed ID: 22866979)
1. Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy.
Piotrowski DW
J Med Chem; 2012 Sep; 55(18):7957-66. PubMed ID: 22866979
[No Abstract] [Full Text] [Related]
2. Mineralocorticoid receptor modulators: a patent review (2007 - 2012).
Collin M; Niemann F; Jaisser F
Expert Opin Ther Pat; 2014 Feb; 24(2):177-83. PubMed ID: 24215301
[TBL] [Abstract][Full Text] [Related]
3. The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy.
Sato A
Hypertens Res; 2015 Jun; 38(6):367-74. PubMed ID: 25762415
[TBL] [Abstract][Full Text] [Related]
4. Esaxerenone: First Global Approval.
Duggan S
Drugs; 2019 Mar; 79(4):477-481. PubMed ID: 30806972
[TBL] [Abstract][Full Text] [Related]
5. Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.
Cox JM; Chu HD; Yang C; Shen HC; Wu Z; Balsells J; Crespo A; Brown P; Zamlynny B; Wiltsie J; Clemas J; Gibson J; Contino L; Lisnock J; Zhou G; Garcia-Calvo M; Bateman T; Xu L; Tong X; Crook M; Sinclair P
Bioorg Med Chem Lett; 2014 Apr; 24(7):1681-4. PubMed ID: 24630411
[TBL] [Abstract][Full Text] [Related]
6. Mineralocorticoid Receptor Antagonists.
Nordqvist A; Granberg KL
Vitam Horm; 2019; 109():151-188. PubMed ID: 30678854
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel non-steroidal reverse indole mineralocorticoid receptor antagonists.
Ogawa AK; Bunte EV; Mal R; Lan P; Sun Z; Crespo A; Wiltsie J; Clemas J; Gibson J; Contino L; Lisnock J; Zhou G; Garcia-Calvo M; Jochnowitz N; Ma X; Pan Y; Brown P; Zamlynny B; Bateman T; Leung D; Xu L; Tong X; Liu K; Crook M; Sinclair P
Bioorg Med Chem Lett; 2016 Jun; 26(12):2866-2869. PubMed ID: 27161805
[TBL] [Abstract][Full Text] [Related]
8. Nonsteroidal antagonists of the mineralocorticoid receptor.
Kolkhof P; Nowack C; Eitner F
Curr Opin Nephrol Hypertens; 2015 Sep; 24(5):417-24. PubMed ID: 26083526
[TBL] [Abstract][Full Text] [Related]
9. Perspective on Nonsteroidal Mineralocorticoid Receptor Antagonism in Diabetic Kidney Disease.
Ghuman JK; Tuttle KR
Kidney360; 2022 Apr; 3(4):744-748. PubMed ID: 35721619
[No Abstract] [Full Text] [Related]
10. Modulating Mineralocorticoid Receptor with Non-steroidal Antagonists. New Opportunities for the Development of Potent and Selective Ligands without Off-Target Side Effects.
Martín-Martínez M; Pérez-Gordillo FL; Álvarez de la Rosa D; Rodríguez Y; Gerona-Navarro G; González-Muñiz R; Zhou MM
J Med Chem; 2017 Apr; 60(7):2629-2650. PubMed ID: 28051871
[TBL] [Abstract][Full Text] [Related]
11. [Mineralocorticoid receptor: an update].
Nagase M
Nihon Rinsho; 2012 Sep; 70(9):1504-9. PubMed ID: 23012795
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.
Hasui T; Ohyabu N; Ohra T; Fuji K; Sugimoto T; Fujimoto J; Asano K; Oosawa M; Shiotani S; Nishigaki N; Kusumoto K; Matsui H; Mizukami A; Habuka N; Sogabe S; Endo S; Ono M; Siedem CS; Tang TP; Gauthier C; De Meese LA; Boyd SA; Fukumoto S
Bioorg Med Chem; 2014 Oct; 22(19):5428-45. PubMed ID: 25187277
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists.
Yang C; Shen HC; Wu Z; Chu HD; Cox JM; Balsells J; Crespo A; Brown P; Zamlynny B; Wiltsie J; Clemas J; Gibson J; Contino L; Lisnock J; Zhou G; Garcia-Calvo M; Bateman T; Xu L; Tong X; Crook M; Sinclair P
Bioorg Med Chem Lett; 2013 Aug; 23(15):4388-92. PubMed ID: 23777778
[TBL] [Abstract][Full Text] [Related]
14. Identification of Morpholino-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-ones as Nonsteroidal Mineralocorticoid Antagonists.
Piotrowski DW; Futatsugi K; Casimiro-Garcia A; Wei L; Sammons MF; Herr M; Jiao W; Lavergne SY; Coffey SB; Wright SW; Song K; Loria PM; Banker ME; Petersen DN; Bauman J
J Med Chem; 2018 Feb; 61(3):1086-1097. PubMed ID: 29300474
[TBL] [Abstract][Full Text] [Related]
15. Predicting the relative binding affinity of mineralocorticoid receptor antagonists by density functional methods.
Roos K; Hogner A; Ogg D; Packer MJ; Hansson E; Granberg KL; Evertsson E; Nordqvist A
J Comput Aided Mol Des; 2015 Dec; 29(12):1109-22. PubMed ID: 26572910
[TBL] [Abstract][Full Text] [Related]
16. Mineralocorticoid-receptor signalling in vascular smooth muscle.
Wu J; Luft FC
Nephrol Dial Transplant; 2013 Jun; 28(6):1360-2. PubMed ID: 23439586
[TBL] [Abstract][Full Text] [Related]
17. Is there a new dawn for selective mineralocorticoid receptor antagonism?
Luther JM
Curr Opin Nephrol Hypertens; 2014 Sep; 23(5):456-61. PubMed ID: 24992570
[TBL] [Abstract][Full Text] [Related]
18. Structure-Based Drug Design of Mineralocorticoid Receptor Antagonists to Explore Oxosteroid Receptor Selectivity.
Nordqvist A; O'Mahony G; Fridén-Saxin M; Fredenwall M; Hogner A; Granberg KL; Aagaard A; Bäckström S; Gunnarsson A; Kaminski T; Xue Y; Dellsén A; Hansson E; Hansson P; Ivarsson I; Karlsson U; Bamberg K; Hermansson M; Georgsson J; Lindmark B; Edman K
ChemMedChem; 2017 Jan; 12(1):50-65. PubMed ID: 27897427
[TBL] [Abstract][Full Text] [Related]
19. Mineralocorticoid receptors mediate cardiac remodelling in morphine-dependent rats.
Mesripour A; Iyer A; Brown L
Basic Clin Pharmacol Toxicol; 2012 Aug; 111(2):75-80. PubMed ID: 22304485
[TBL] [Abstract][Full Text] [Related]
20. Identification of spirooxindole and dibenzoxazepine motifs as potent mineralocorticoid receptor antagonists.
Lotesta SD; Marcus AP; Zheng Y; Leftheris K; Noto PB; Meng S; Kandpal G; Chen G; Zhou J; McKeever B; Bukhtiyarov Y; Zhao Y; Lala DS; Singh SB; McGeehan GM
Bioorg Med Chem; 2016 Mar; 24(6):1384-91. PubMed ID: 26897089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]